|
Andrew is an investor and entrepreneur with 18 years of experience building, restructuring and acquiring companies in life sciences. A founding member of InCube’s venture fund, Andrew is also an advisor to InCube Labs, LLC, which develops breakthrough medical technologies under the guidance of Mir Imran.
Prior to co-founding DFJ InCube Ventures, Andrew served as a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. These investments include Intrapace (obesity), Penumbra (ischemic stroke), Sonoma Orthopedic Products (bone repair), SwitchGear Genomics (gene regulation) & Spinal Modulation (pain management). Andrew has also been an active angel investor in a broader variety of ventures.
Earlier in his career, Andrew and his partner Nathan Hamilton ran and turned around Operon Technologies, ultimately selling it to QIAGEN, NV for $150M. During his tenure there, Andrew built a global sales force from scratch, grew revenues of synthetic DNA products from $13 to $40M in two years, and launched the world’s first whole-genome research tools for malaria and tuberculosis. He subsequently acquired a company in Japan for QIAGEN, and restructured the combined sales force. Prior to Operon, Andrew held several roles in research operations at Genentech, Inc. and co-founded a gene design business in agricultural biotechnology. He has founded other companies, sat on a wide range of boards, and developed strategies for healthcare firms as a consultant.
Andrew holds a Masters of Business Administration from Harvard University and a Bachelor’s from the University of California at Berkeley.
|
